Thiamine and Parkinson's disease

Journal of the Neurological Sciences

Volumn 316, Issue 1-2, 2012, Pages 1-8

  Lu'o'ng, Khanh Vinh Quôc ^a   Nguyên, Lan Thi Hoàng ^a  

^a Vietnamese American Medical Research Foundation   (United States)

Author keywords

Movement disorder; Parkinson's disease; Thiamine; Transketolase

Indexed keywords

CALCIUM CHANNEL L TYPE; CYCLOOXYGENASE 2; DIHYDROLIPOAMIDE DEHYDROGENASE; DJ 1 PROTEIN; EXCITATORY AMINO ACID TRANSPORTER; HEME OXYGENASE 1; MATRIX METALLOPROTEINASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NITRIC OXIDE SYNTHASE; OXOGLUTARATE DEHYDROGENASE; PROSTAGLANDIN; PROTEIN P53; REACTIVE OXYGEN METABOLITE; THIAMINE; UBIDECARENONE;

CELL METABOLISM; CHROMOSOME 7; GENETIC ANALYSIS; GENOMICS; INFLAMMATION; NEUROPROTECTION; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

ANIMALS; BIOLOGICAL MARKERS; CYCLOOXYGENASE 2; HUMANS; OXIDATIVE STRESS; PARKINSON DISEASE; REACTIVE OXYGEN SPECIES; THIAMINE;

EID: 84859443870     PISSN: 0022510X     EISSN: 18785883     Source Type: Journal    
DOI: 10.1016/j.jns.2012.02.008     Document Type: Review

References (151)

1. T. Tadano, Y. Abe, Y. Morikawa, T. Asao, M. Hozumi, and N. Takahashi Involvement of dopaminergic neurons in mouse-killing aggression in rats Methods Find Exp Clin Pharmacol 19 1997 527 531
2. K. Onodera Effects of decarboxylase inhibitors on muricidal suppression by L-dopa in thiamine deficient rats Arch Int Pharmacodyn Ther 285 1987 263 276
3. F.J. Jiménez-Jimnénez, J.A. Molina, A. Hernánz, E. Hernández-Vivancos, F. de Bustos, and B. Barcenilla Cerebrospinal fluid levels of thiamine in patients with Parkinson's disease Neurosci Lett 271 1999 33 36
4. B. Sjöquist, H.A. Johnson, A. Neri, and S. Lindén The influence of thiamine deficiency and ethanol on rat brain catecholamines Drug Alcohol Depend 22 1988 167 193
5. D.D. Mousseau, V.L. Raghsvendra Rao, and R.F. Butterworth Vesicular dysfunction during experimental thiamine deficiency is indicated by alterations in dopamine metabolism Eur J Pharmacol 317 1996 263 267
6. H. Yamashita, Y.-X. Zhang, and S. Nakamura The effects of thiamine and its phosphate esters on dopamine release in the rat striatum Neurosci Lett 158 1993 229 231
7. V. Bonifati, P. Rizzu, M.J. van Baren, O. Schaap, G.J. Breedveld, and E. Krieger Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism Science 299 2003 256 259
8. R. Hering, K.M. Strauss, X. Tao, A. Bauer, D. Woitalla, and E.M. Mietz Novel homozygous p.E64D mutation in DJ1 in early onset Parkinson disease Hum Mutat 24 2004 321 329
9. K.-J. Oh, Y.-S. Park, K.-A. Lee, Chung Yong Je, and T.-J. Cho Molecular characterization of a thiJ-like gene in Chinese cabbage J Biochem Mol Biol 37 2004 343 350
10. S. Bandyopadhyay, and M.R. Cookson Evolutionary and functional relationships within the DJ1 superfamily BMC Evol Biol 6 2004 6
11. P. Shashidharan, G.W. Huntley, T. Meyer, J.H. Morrison, and A. Plaitakis Neuron-specific human glutamate transporter: molecular cloning, characterization and expression in human brain Brain Res 662 1994 245 250
12. K. Aoyama, S.W. Suh, A.M. Hamby, J. Liu, W.Y. Chan, and Y. Chen Neuronal glutathione deficiency and age-dependent neurodegeneration in the EAAC1 deficient mouse Nat Neurosci 9 2006 119 126
13. D.B. Re, J. Boucraut, D. Samuel, S. Birman, G.L. Kerkerian-Le, and L. Had-Aissouni Glutamate transport alteration triggers differentiation-state selective oxidative death of cultured astrocytes: a mechanism different from excitotoxicity depending on intracellular GSH contents J Neurochem 85 2003 1159 1170
14. I. Nafia, D.B. Re, F. Masmejean, C. Melon, P. Kachidian, and L.K.-L. Goff Preferential vulnerability of mesencephalic dopamine neurons to glutamate transporter dysfunction J Neurochem 105 2008 484 496
15. J. Sian, D.T. Dexter, A.J. Lees, S. Daniels, Y. Agid, and F. Jayoy-Agid Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia Ann Neurol 36 1994 348 355
16. A. Plaitakis, and P. Shashidharan Glutamate transport and metabolism in dopaminergic neurons of substantia nigra: implications for the pathogenesis of Parkinson's disease J Neurol 247 2000 II25 II35
17. A.S. Hazell, K.G. Todd, and R.F. Butterworth Mechanisms of neuronal cell death in Wernicke's encephalopathy Metab Brain Dis 13 1998 97 122
18. Y. Mizuno, S. Matuda, H. Yoshino, H. Mori, N. Hattori, and S.-I. Ikebe An immunohistochemical study on α-ketoglutarate dehydrogenase complex in Parkinson's disease Ann Neurol 35 1994 204 210
19. Y. Mizuno, S. Ikebe, N. Hattori, Y. Nakagawa-Hattori, H. Mochizuki, and M. Tanaka Role of mitochondria in the etiology and pathogenesis of Parkinson's disease Biochim Biophys Acta 1271 1995 265 274
20. K.S. McNaught, C. Altomare, S. Cellamare, A. Carotti, P.A. Carrupt, and B. Testa Inhibition of alpha-ketoglutarate dehydrogenase by isoquinoline derivatives structurally related to methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) Neuroreport 6 1995 1105 1108
21. X.M. Shen, H. Li, and G. Dryhurst Oxidative metabolites of 5-S-cysteinyldopamine inhibit the alpha-ketoglutarate dehydrogenase complex: possible relevance to the pathogenesis of Parkinson's disease J Neural Transm 107 2000 859 878
22. K.F. Sheu, N.Y. Calingasan, J.G. Lindsay, and G.E. Gibson Immunochemical characterization of the deficiency of the alpha-ketoglutarate dehydrogenase complex in thiamine-deficient rat brain J Neurochem 70 1998 1143 1150
23. Q. Shi, S.S. Karuppagounder, H. Xu, D. Pechman, H. Chen, and G.E. Gibson Responses of the mitochondrial alpha-ketoglutarate dehydrogenase complex to thiamine deficiency may contribute to regional selective vulnerability Neurochem Int 50 2007 921 931
24. P. Bubber, Z.J. Ke, and G.E. Gibson Tricarboxylic acid cycle enzymes following thiamine deficiency Neurochem Int 45 2004 1021 1028
25. F.J. Jimenez-Jimenez, J.A. Molina, F. de Bustos, A. Garcia-Redondo, C. Gomez-Escalonilla, and A. Martinez-Salio Serum levels of coenzyme Q10 in patients with Parkinson's disease J Neural Transm 107 2000 177 181
26. M. Varghese, M. Pandey, A. Samanta, P.K. Gangopadhyay, and K.P. Mohanakumar Reduced NADH coenzyme Q dehydrogenase activity in platelets of Parkinson's disease, but not Parkinson plus patients, from an Indian population J Neurol Sci 279 2009 39 42
27. I.P. Hargreaves, A. Lane, and P.M. Sleiman The coenzyme Q10 status of the brain regions of Parkinson's disease patients Neurosci Lett 447 2008 17 19
28. C. Isobe, T. Abe, and Y. Terayama Levels of reduced and oxidized coenzyme Q-10 and 8-hydroxy-2′-deoxyguanosine in the cerebrospinal fluid of patients with living Parkinson's disease demonstrate that mitochondrial oxidative damage and/or oxidative DNA damage contributes to the neurodegenerative process Neurosci Lett 469 2010 159 163
29. P. Koocumchoo, S. Sharma, J. Porter, P. Gavitrapong, and M. Ebadi Coenzyme Q(10) provides neuroprotection in iron-induced apoptosis in dopaminergic neurons J Mol Neurosci 28 2006 125 141
30. C. Cleren, L. Yang, B. Lorenzo, N.Y. Calingasan, A. Schomer, and A. Sireci Therapeutic effects of coenzyme Q10 (CoQ10) and reduced CoQ10 in the MPTP model of Parkinsonism J Neurochem 104 2008 1613 1621
31. M. Somayajulu-Nitu, J.K. Sandhu, J. Cohen, M. Sikorska, and T.S. Sridhar Paraquat induces oxidative stress, neuronal loss in substantia nigra region and parkinsonism in adult rats: neuroprotection and amelioration of symptoms by water-soluble formulation of coenzyme Q10 BMC Neurosci 10 2009 88
32. B.K. Binukuman, N. Gupta, A. Bal, and K.D. Gill Protection of dichlorvos induced oxidative stress and nigrostriatal neuronal death by chronic Coenzyme Q(10) pretreatment Toxicol Appl Pharmacol 256 2011 73 82
33. A.T. Diplock, J. Bunyan, J. Green, and E.E. Edwin Studies on vitamin E. 7. The effect of thiamine, riboflavin and pantothetic acid on ubiquinone and ubichromenol in the rat Biochem J 79 1961 105 108
34. M. Dhanasekaran, C.B. Albano, L. Pellet, S.S. Karuppagounder, S. Uthayathas, and V. Suppiramaniam Role of lipoamide dehydrogenase and metallothionein on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity Neurochem Res 33 2008 980 984
35. P. Klinenyi, A.A. Starkov, N.Y. Calingasan, G. Gardian, S.E. Browne, and L. Yang Mice deficient in dihydrolipoamide dehydrogenase show increased vulnerability to MPTP, malonate and 3-nitropropionic acid neurotoxicity J Neurochem 88 2004 1352 1360
36. O.N. Elpeleg, W. Ruitenbeek, C. Jacobs, V. Barash, D.C. De Vivo, and N. Amir Congenital lacticacidemia caused by lipoamide dehydrogenase deficiency with favourable outcome J Pediatr 126 1995 72 74
37. R. Matalon, D.A. Stumpf, K. Michals, R.D. Hart, J.K. Parks, and S.I. Goodman Lipoamine dehydrogenase deficiency with primary lactic acidosis: favorable response to treatment with oral lipoic acid J Pediatr 104 1984 65 69
38. E. Quintana, M. Pineda, A. Font, M.A. Vilaseca, F. Tort, and A. Ribes Dihydrolipoamide dehydrogenase (DLD) deficiency in a Spanish patient with myopathic presentation due to a new mutation in the interface domain J Inherit Metab Dis Jul 21 2010 [Epub ahead of print]
39. L. Benmoyal-Segal, and H. Soreq Gene-environment interactions in sporadic Parkinson's disease J Neurochem 97 2006 1740 1755
40. G. Otulakowski, B.H. Robinson, and H.F. Willard Gene for lipoamide dehydrogenase maps to human chromosome 7 Somat Cell Mol Genet 14 1988 411 414
41. K. Nosaka, M. Onozuka, N. Kakazu, S. Hibi, H. Nishimura, and H. Nishino Isolation and characterization of a human thiamine pyrophosphokinase cDNA Biochim Biophys Acta 1517 2001 292 297
42. I.E. Whitney, M.A. Raven, D.C. Ciobanu, R.W. Williams, and B.E. Reese Multiple genes on chromosome 7 regulate dopaminergic amacrine cell number in the mouse retina Invest Ophthalmol Vis Sci 50 2009 1996 2003
43. M. Mogi, T. Kondo, Y. Mizuno, and T. Nagatsu p53 protein, interferon-gamma, and NF-kappaB levels are elevated in the parkinsonian brain Neurosci Lett 414 2007 94 97
44. D. Daily, A. Barzilai, D. Offen, A. Kamsler, E. Melamed, and I. Ziv The involvement of p53 in dopamine-induced apoptosis of cerebellar granule neurons and leukemic cells overexpressing p53 Cell Mol Neurobiol 19 1999 261 276
45. K. Nakaso, Y. Yoshimoto, H. Yano, T. Takeshima, and K. Nakashima p53-mediated mitochondrial dysfunction by proteasome inhibition in dopaminergic SH-SY5Y cells Neurosci Lett 354 2004 213 216
46. W. Duan, X. Zhu, B. Ladenheim, Q.S. Yu, Z. Guo, and J. Oyler p53 inhibitors preserve dopamine neurons and motor in experimental parkinsonism Ann Neurol 52 2002 597 606
47. P.K. Lo, J.Y. Chen, P.P. Tang, J. Lin, C.H. Lin, and L.T. Su Identification of a mouse thiamine transporter gene as a direct transcriptional target for p53 J Biol Chem 276 2001 37186 37193
48. + modulates p53 DNA binding specificity and function Mol Cell Biol 24 2004 9958 9967
49. Z. Yang, J. Ge, W. Yin, H. Shen, H. Liu, and Y. Guo The expression of p53, MDM2 and Ref1 gene in cultured retina neurons of SD rats treated with vitamin B1 and/or elevated pressure Yan Ke Xue Bao 20 2004 259 263 [Article in Chinese]
50. D.G. Changaris, L.C. Keil, and W.B. Severs Angiotensin II immunohistochemistry of the rat brain Neuroendocrinology 25 1978 257 274
51. D.P. Healy, and M.P. Printz Distribution of immunoreactive angiotensin II, angiotensin I, angiotensinogen, and renin in the central nervous system of intact and nephrectomized rats Hypertension 6 Suppl. 1 1984 130 136
52. D. Ganten, K. Hermann, D. Bayer, T. Unger, and R.R. Lang Angiotensin synthesis in the brain and increased turnover in hypertensive rats Science 221 1983 869 871
53. V.J. Dzau, J. Ingelfinger, R.E. Pratt, and K.E. Ellison Identification of renin and angiotensinogen messenger RNA sequences in rat brain Hypertension 8 1986 544 548
54. G.S. Zubenko, L. Volicer, L.K. Direnfeld, M. Freeman, P.J. Langlais, and R.A. Nixon Cerebrospinal fluid levels of angiotensin-converting enzyme in Alzheimer's disease, Parkinson's disease and progressive supranuclear palsy Brain Res 328 1985 215 221
55. C.H. Konings, M.A. Kuiper, P.L.M. Bergmans, A.-M. Grijpma, G.J. van Kamp, and E.C. Wolters Increased angiotensin-converting enzyme activity in cerebrospinal fluid of treated patients with Parkinson's disease Clin Chim Acta 231 1994 101 106
56. R. Kurosaki, Y. Muramatsu, H. Kato, Y. Wanatabe, Y. Imai, and Y. Itoyama Effect of angiotensin-converting enzyme inhibitor perindopril on interneurons in MPTP-treated mice Eur Neuropsychopharmacol 15 2005 57 67
57. T.A. Jenkins, J.Y.F. Wong, D.W. Howells, F.A.O. Mendelsohn, and S.Y. Chai Effect of chronic angiotensin-converting enzyme inhibition on striatal dopamine content in the MPTP-treated mouse J Neurochem 73 1999 214 219
58. K.A. Reardon, F.A. Mendelsohn, S.Y. Chai, and M.K. Horne The angiotensin converting enzyme (ACE) inhibitor, perindopril, modifies the clinical features of Parkinson's disease Aust N Z J Med 30 2000 48 53
59. J.-J. Lin, K.-C. Yueh, D.-C. Chang, and S.-Z. Lin Association between genetic polymorphism of angiotensin-converting enzyme and Parkinson's disease J Neurol Sci 199 2002 25 29
60. J.-J. Lin, K.-C. Yueh, S.-Z. Lin, H.-J. Harn, and J.-T. Liu Genetic polymorphism of the angiotensin converting enzyme and L-dopa-induced adverse effects in Parkinson's disease J Neurol Sci 252 2007 130 134
61. G.D. Mellick, D.D. Buchanan, S.J. McCann, D.R. Davis, D.G. Le Couteur, and D. Chan The ACE deletion polymorphism is not associated with Parkinson's disease Eur Neurol 41 1999 103 106
62. E. Pascale, C. Purcaro, E. Passarelli, R. Guglielmi, A.R. Vestri, and F. Passarelli Genetic polymorphism of angiotensin-converting enzyme is not associated with the development of Parkinson's disease and L-dopa-induced adverse effects J Neurol Sci 276 2009 18 21
63. T. Tanaka, K. Sohmiya, T. Kono, F. Terasaki, R. Horie, and Y. Ohkaru Thiamine attenuates the hypertension and metabolic abnormalities in CD36-defective SHR: uncoupling of glucose oxidation from cellular entry accompanied with enhanced protein)-GlcNAcylation in CD36 deficiency Mol Cell Biochem 299 2007 23 35
64. J.R. Hascalovici, J. Vaya, S. Khatib, C.A. Holcroft, H. Zukor, and W. Song Brain sterol dys-regulation in sporadic AD and MCI: relationship to heme oxygenase-1 J Neurochem 110 2009 1241 1253
65. D.E. Baranano, and S.H. Snyder Neural roles for heme oxygenase: contrasts to nitric oxide synthase Proc Natl Acad Sci U S A 98 2001 10996 11002
66. R. Castellani, M.A. Smith, P.L. Richey, and G. Perry Glycoxidation and oxidative stress in Parkinson disease and diffuse Lewy body disease Brain Res 737 1996 195 200
67. I. Mateo, J. Infante, P. Sánchez-Juan, I. García- Gorostiaga, E. Rodríguez-Rodríguez, and J.L. Vázquez- Higuera Serum heme oxygenase-1 levels are increased in Parkinson's disease but not in Alzheimer's disease Acta Neurol Scand 121 2010 136 138
68. N.Y. Calingasan, and G.E. Gibson Dietary restriction attenuates the neuronal loss, induction of heme oxygenase-1 and blood-brain barrier breakdown induced by impaired oxidative metabolism Brain Res 885 2000 62 69
69. N.Y. Calingasan, P.L. Huang, H.S. Chun, A. Fabian, and G.E. Gibson Vascular factors are critical in selective neuronal loss in an animal model of impaired oxidative metabolism J Neuropathol Exp Neurol 59 2000 207 217
70. Z.J. Ke, L.A. DeGiorgio, B.T. Volpe, and G.E. Gibson Reversal of thiamine deficiency-induced neurodegeneration J Neuropathol Exp Neurol 62 2003 195 207
71. J. Soós, J.I. Engelhardt, L. Siklós, L. Havas, and K. Majtényi The expression of PARP, NF-kappa B and parvalbumin is increased in Parkinson disease Neuroreport 15 2004 1715 1718
72. H. Wang, M. Shimoji, S.-W. Yu, T.M. Dawson, and V.L. Dawson Apoptosis inducing factor and PARP-mediated injury in the MPTP mouse model of Parkinson's disease Ann N Y Acad Sci 991 2003 132 139
73. A.S. Mandir, S. Przedborski, V. Jackson-Lewis, Z.-Q. Wang, C.M. Simbulan-Rosenthal, and M.E. Smulson Poly(ADP-ribose) polymerase activation mediates 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism Proc Natl Acad Sci U S A 96 1999 5774 5779
74. A. Iwashita, K. Mihara, S. Yamazaki, S. Matsuura, J. Ishida, and H. Yamamoto A new Poly(ADP-ribose) polymerase inhibitor, FR261529 [2-(4-chlorophenyl)-5-quinoxalinecarboxamide], ameliorates methamphetamine- induced dopaminergic neurotoxicity in mice J Pharmacol Exp Ther 310 2004 1114 1124
75. H. Yokoyama, H. Kuroiwa, T. Tsukada, H. Uchida, H. Kato, and T. Araki Poly(ADP-ribose) polymerase inhibitor can attenuate the neuronal death after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice J Neurosci Res 88 2010 1522 1536
76. J. Infante, P. Sánchez-Juan, I. Mateo, E. Rodríguez- Rodríguez, C. Sánchez-Quintana, and J. Llorca Poly(ADP-ribose) polymerase-1 (PARP-1) genetic variants are protective against Parkinson's disease J Neurol Sci 256 2007 68 70
77. B.H. Shin, S.H. Choi, E.Y. Cho, M.J. Shin, K.C. Hwang, and H.K. Cho Thiamines attenuates hypoxia-induced cell death in cultured neonatal rat cardiomyocytes Mol Cells 18 2004 133 140
78. U.C.S. Yadav, N.M. Kalariya, S.K. Srivastava, and K.V. Ramana Protective role of benfotiamine, a fat soluble vitamin B1 analogue, in the lipopolysaccharide-induced cytotoxic signals in murine macrophages Free Radic Biol Med 48 2010 1423 1434
79. M. Frédérich, D. Delvaux, T. Gigliobianco, M. Gangolf, G. Dive, and G. Mazzuchelli Thiaminylated adenine nucleotides FEBS J 276 2009 3256 3268
80. T. Tanaka, D. Yamamoto, T. Sato, S. Tanaka, K. Usui, and M. Manabe Adenosine thiamine triphosphate (AThTP) inhibits Poly(ADP-Ribose) polymerase-1 (PARP-1) activity J Nutr Sci Vitaminol 57 2011 192 196
81. D.P. Figlewicz, S.B. Evans, J. Murphy, M. Hoen, and D.G. Baskin Expression of receptors for insulin and leptin in the ventral tegmental area/substantia nigra (VTA/SN) of the rat Brain Res 964 2003 107 115
82. M. Takahashi, T. Yamada, I. Tooyama, I. Moroo, H. Kimura, and T. Yamamoto Insulin receptor mRNA in the substantia nigra in Parkinson's disease Neurosci Lett 204 1996 201 204
83. R. Sandyk The relationship between diabetes mellitus and Parkinson's disease Int J Neurosci 69 1993 125 130
84. M. D'amelio, P. Ragonese, G. Callari, N.D. Benedetto, B. Palmeri, and V. Terruso Diabetes preceding Parkinson's disease onset. A case-control study Parkinsonism Relat Disord 15 2009 660 664
85. Q. Xu, Y. Park, X. Huang, A. Hollenbeck, A. Blair, and A. Schatzkin Diabetes and risk of Parkinson's disease Diabetes Care 34 2011 910 915
86. E. Schernhammer, J. Hansen, K. Rugbjerg, L. Wermuth, and B. Ritz Diabetes and the risk of developing Parkinson's disease in Denmark Diabetes Care 34 2011 1102 1108
87. K.M. Powers, T. Smith-Weller, G.M. Franklin, W.T. Longstregh Jr., P.D. Swanson, and H. Checkoway Diabetes, smoking, and other medical conditions in relation to Parkinson's risk Parkinsonism Relat Disord 12 2006 185 189
88. C. Becker, G.P. Brobert, S. Johansson, S.S. Jick, and C.R. Meier Diabetes in patients with idiopathic Parkinson's disease Diabetes Care 31 2008 1808 1812
89. M.A. Fishel, G.S. Watson, T.J. Montine, Q. Wang, P.S. Green, and J.J. Kulstad Hyperinsulinemia provokes synchronous increases in central inflammation and β-amyloid in normal adults Arch Neurol 62 2005 1539 1544
90. J.K. Morris, H. Zhang, A.A. Gupte, G.L. Bomhoff, J.A. Stanford, and P.C. Geiger Measures of insulin resistance in a 6-hydroxydopamine model of Parkinson's disease Brain Res 1240 2008 185 195
91. K.R. Wilhelm, K. Yanamandra, M.A. Gruden, V. Zamotin, M. Malisauskas, and V. Casaite Immune reactivity towards insulin, its amyloid and protein S100B in blood sera of Parkinson's disease patients Eur J Neurol 14 2007 327 334
92. M.H. Van Woert, and P.S. Mueller Glucose, insulin, and free fatty acid metabolism in Parkinson's disease treated with levodopa Clin Pharmacol Ther 12 1971 360 367
93. E.A. Boyd III, H.E. Lebovitz, and J.M. Feldman Endocrine function and glucose metabolism in patients with Parkinson's disease and their alternation by L-dopa J Clin Endocrinol Metab 33 1971 829 837
94. E. Murzi, Q. Contreras, L. Teneud, B. Valecillos, M.A. Parada, and M.P. De Parada Diabetes decreases limbic extracellular dopamine in rats Neurosci Lett 202 1996 141 144
95. H. Shimizu, Y. Shimomura, M. Takahashi, I. Kobayashi, and S. Kobayashi Dopamine receptor in the streptozotocin-induced diabetic rats Exp Clin Endocrinol 95 1990 263 266
96. J.D. Watson, and D.Y. Dako Erythrocyte transketolase activity in adult Ghanaian subjects Clin Chim Acta 59 1975 55 61
97. G. Valerio, A. Franzese, V. Poggi, C Patrini, U. Laforenza, and A. Tenore Lipophylic thiamine treatment in long-standing insulin-dependent diabetes mellitus Acta Diabetol 36 1999 73 76
98. M. Berant, D. Berkovitz, H. Mandel, O. Zinder, and D. Mordohovich Thiamine status of the offspring of diabetic rats Pediatr Res 23 1988 574 575
99. J.A. Clark, I. Burny, A.P. Sarnaik, and T.K. Audhya Acute thiamine deficiency in diabetic ketoacidosis: diagnosis and management Pediatr Crit Care Med 7 2006 595 599
100. D. Oriot, C. Wood, R. Gottesman, and G. Huault Severe lactic acidosis related to acute thiamine deficiency JPEN J Parenter Enteral Nutr 15 1991 105 109
101. N. Saito, M. Kimura, A. Kuchiba, and Y. Itokawa Blood thiamine levels in outpatients with diabetes mellitus J Nutr Sci Vitaminol 33 1987 421 430
102. B.M.S. Kjøsen, and S.H. Seim The transketolase assay of thiamine in some diseases Am J Clin Nutr 30 1977 1591 1596
103. P.J. Thornalley, R. Babaei-Jadidi, H. Al Ali, N. Rabbani, A. Antonysunil, and J. Larkin High prevalence of low thiamine concentration in diabetes linked to a marker of vascular disease Diabetologia 50 2007 2164 2170
104. H. Baker, O. Frank, T. Chen, S. Feingold, B. DeAngelis, and E. Baker Vitamin content of some normal human brain segments J Neurosci Res 11 1984 419 435
105. U. Laforenza, C. Patrini, M. Poloni, P. Mazzarello, M. Ceroni, and D.C. Gajdusek Thiamine- mono- and pyrophosphatase activities from brain homogenate of Guamanian amyotrophic lateral sclerosis and parkinsonism-dementia patients J Neurol Sci 109 1992 156 161
106. M. Gold, R.A. Hauser, and M.F. Chen Plasma thiamine deficiency associated with Alzheimer's disease but not Parkinson's disease Metab Brain Dis 13 1998 43 53
107. B. Kalidass, R. Sunnathkal, D.V. Rangashamanna, and R. Paraswani Atypical Wernicke's encephalopathy showing involvement of substantia nigra J Neuroimaging 2010 Article first published online: 1 Dec 2010, doi: 10.1111/j.1552-6569.2010.00545.x
108. H. Merkin-Zaborsky, G. Ifergane, S. Frisher, S. Valdman, Y. Herishanu, and I. Wirguin Thiamine-responsive acute neurological disorders in nonalcoholic patients Eur Neurol 45 2001 34 37
109. M.A. Cowen, M. Green, D.N. Bertollo, and K. Abbott A treatment for tardive dyskinesia and some other extrapyramidal symptoms J Clin Psychopharmacol 17 1997 190 193
110. D.J. Surmeier Calcium, ageing, and neuronal vulnerability in Parkinson's disease Lancet Neurol 6 6 2007 933 938
111. 2-dopamine receptor modulation of high voltage-activated calcium current in striatal medium spiny neurons from animal models of Parkinson's disease Neuroscience 177 2011 240 251
112. C.R. Lee, and J.M. Tepper A calcium-activated nonselective cation conductance underlies the plateau potential in rat substantia nigra GABAergic neuron J Neurosci 27 2007 6531 6541
113. C.S. Chan, T.S. Gertler, and D.J. Surmeier A molecular basis for the increased vulnerability of substantia nigra dopamine neurons in aging and Parkinson's disease Mov Disord 25 2010 S63 S70
114. C.S. Chan, T.S. Gertler, and D.J. Surmeier Calcium homeostasis, selective vulnerability and Parkinson's disease Trends Neurosci 32 2009 249 256
115. A. Kupsch, M. Gerlach, S.C. Pupeter, J. Sautter, A. Dirr, and G. Arnold Pretreatment with nimodipine prevents MPTP-induced neurotoxicity at the nigral, but not at the striatal level in mice Neuroreport 6 1995 621 625
116. A. Kupsch, J. Sautter, J. Schwarz, P. Riederer, M. Gerlach, and W.H. Oertel 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced neurotoxicity in non-human primates is antagonized by pretreatment at the nigral, but not at the striatal level Brain Res 741 1996 185 196
117. 2 + channel reduces development of abnormal involuntary movement in the rat model of L-3,4-dihydroxyphenylalanine- induced dyskinesia Biol Psychiatry 65 2009 518 526
118. A.S. Hazell, A.M. Hakim, M.K. Senterman, and M.J. Hogan Regional activation of L-type voltage-sensitive calcium channels in experimental thiamine deficiency J Neurosci Res 52 1998 742 749
119. J.A. McClain, L.L. Phillips, and H.L. Fillmore Increased MMP-3 and CTGF expression during lipopolysaccharide-induced dopaminergic neurodegeneration Neurosci Lett 460 2009 27 31
120. S. Lorenzl, N. Caligasan, L. Yang, D.S. Albers, S. Shugama, and J. Gregorig Matrix metalloproteinase-9 is elevated in 1-methyl-4-1,2,3,6- tetrahydropyridine-induced parkinsonism in mice Neuromolecular Med 5 2004 119 132
121. S.Y. Kim, M.S. Woo, J.S. Park, J.W. Huyn, Y.S. Kim, and H.S. Kim The neuroprotective role of tissue inhibitor of metalloproteinase-2 in MMP+- or 6-OHDA-treated SK-N-BE(2)C and SH-SY5Y human neuroblastoma cells Neurosci Lett 468 2010 136 140
122. S. Kim, M. Moon, and S. Park Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease J Endocrinol 202 2009 431 439
123. É. Beauchesne, P. Desjardins, A.S. Hazell, and R.F. Butterworth eNOS gene deletion restores blood0brain barrier integrity and attenuates neurodegeneration in the thiamine-deficient mouse brain J Neurochem 111 2009 452 459
124. Y. Kohda, H. Shirakawa, K. Yamane, K. Otsuka, T. Kono, and F. Terasaki Prevention of incipient diabetic cardiomyopathy by high-dose thiamine J Toxicol Sci 33 2008 459 472
125. S. Tarallo, E. Beltramo, E. Berrone, P. Dentelli, and M. Porta Effects of high glucose and thiamine on the balance between matrix metalloproteinases and their tissue inhibitors in vascular cells Acta Diabetol 47 2010 105 111
126. T. Kobayashi, K. Notoya, A. Nakamura, and K. Akimoto Fursultiamine, a vitamin B1 derivative, enhances chondroprotective effects of glucosamine hydrochloride and chondroitin sulfate in rabbit experimental osteoarthritis Inflamm Res 54 2005 249 255
127. E. Ricciotti, and G.A. Fitzgerald Prostaglandins and inflammation Arterioscler Thromb Vasc Biol 31 2011 986 1000
128. M.B. Mattammal, R. Strong, V.M. Lakshmi, H.D. Chung, and A.H. Stephenson Prostaglandin H synthetase-mediated metabolism of dopamine: implication for Parkinson's disease J Neurochem 64 1995 1645 1654
129. T. Wang, Z. Pei, W. Zhang, B. Liu, R. Langenbach, and C. Lee MMP-induced COX-2 activation and subsequent neurodegeneration FASEB J 19 2005 1134 1136
130. 2 neurotoxicity J Neurosci Res 85 2007 3109 3117
131. C. Knott, G. Stern, and G.P. Wilkin Inflammatory regulators in Parkinson's disease: iNOS, lipocortin-1, and cyclooxygenases-1 and -2 Mol Cell Neurosci 16 2000 724 739
132. P. Teishmann, K. Tieu, D.K. Choi, D.C. Wu, A. Naini, and S. Hunot Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration Proc Natl Acad Sci U S A 100 2003 5473 5478
133. P. Teishmann, and B. Ferger Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease Synapse 39 2001 167 174
134. H. Chen, S.M. Zhang, M.A. Hernan, M.A. Schwatzschild, W.C. Willet, and G.A. Colditz Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease Arch Neurol 60 2003 1059 1064
135. B. Gu, P. Desjardins, and R.F. Butterworth Selective increase of neuronal cyclooxygenase-2 (COX-2) expression in vulnerable brain regions of rats with experimental Wernicke's encephalopathy: effect of nimesulide Metab Brain Dis 23 2008 175 187
136. U.C. Yaday, S. Subramanyam, and K.V. Ramana Prevention of endotoxin-induced uveitis in rats by benfotiamine, a lipophilic analogue of vitamin B1 Invest Ophthalmol Vis Sci 50 2009 2276 2282
137. U.C. Yaday, N.M. Kalariya, S.K. Srivastava, and K.V. Ramana Protective role of benfotiamine, a fat-soluble vitamin B1 analogue, in lipopolysaccharide- induced cytotoxic signals in murine macrophages Free Radic Biol Med 48 2010 1423 1434
138. A. Prigione, I.U. Isaias, A. Galbussera, B. Begni, G. Pezzoli, and C. Ferrarese Increased oxidative stress in lymphocytes from untreated Parkinson's disease Parkinsonism Relat Disord 15 2009 327 328
139. D.T. Dexter, C.J. Carter, F.R. Wells, F. Javoy-Agid, Y. Agid, and A. Lees Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease J Neurochem 52 1989 381 389
140. D.T. Dexter, A.E. Holley, W.D. Flitter, T.F. Slater, S.R. Wells, and S.E. Daniel Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: an HPLC and ESR study Mov Disord 9 1994 92 97
141. H. Saggu, J. Cooksey, D. Dexter, F.R. Wells, A. Lees, and P. Jenner A selective increase in particulate superoxide dismutase activity in parkinsonian substantia nigra Neurochemistry 53 1989 692 697
142. N.Y. Calingasan, W.J. Chun, L.C. Park, and G.E. Gibson Oxidative stress is associated with region-specific neuronal death during thiamine deficiency J Neuropathol Exp Neurol 58 1999 946 958
143. P.I. Lukienko, N.G. Mel'nichenko, I.V. Zverinskii, and S.V. Zabrodskaya Antioxidant properties of thiamine Bull Exp Biol Med 130 2000 874 876
144. S. Hunot, F. Boissiere, B. Faucheux, B. Brugg, A. Mouatt-Prigent, and Y. Agid Nitric oxide synthase and neuronal vulnerability in Parkinson's disease Neuroscience 72 1996 355 363
145. M.K. Barthwal, N. Srivastava, R. Shukla, D. Nag, P.K. Seth, and R.C. Srimal Polymorphonuclear leukocyte nitrate content and antioxidant enzymes in Parkinson's disease Acta Neurol Scand 100 1999 300 304
146. S. Singh, T. Das, A. Ravindran, R.K. Chaturvedi, Y. Shukla, and A.K. Agarwal Involvement of nitric oxide in neurodegeneration: a study on the experimental models of Parkinson's disease Redox Rep 10 2005 103 109
147. Y. Muramatsu, R. Kurosaki, H. Wanatabe, M. Michimata, M. Matsubara, and Y. Imai Cerebral alterations in a MPTP-mouse model of Parkinson's disease-an immunocytochemical study J Neural Transm 110 2003 1129 1144
148. J.B. Schulz, R.T. Mathews, M.M. Muqit, S.E. Browne, and M.F. Beal Inhibition of neuronal nitric acid synthase by 7-nitroindazole protect against MPTP-induced neurotoxicity in mice J Neurochem 64 1995 936 939
149. T. Dehmer, J. Lindenau, S. Haid, J. Dichgans, and J.B. Schulz Deficiency of inducible nitric oxide synthase protects against MPTP toxicity in vivo J Neurochem 74 2000 2213 2216
150. D. Kaur, D. Lee, S. Ragapolan, and J.K. Andersen Glutathione depletion in immortalized midbrain-derived dopaminergic neurons results in increases in the labile iron pool: implications for Parkinson's disease Free Radic Biol Med 46 2009 593 598
151. K.V.Q. Lu'o'ng ng, and L.T.H. Nguyê∼n The impact of thiamine treatment on generalized anxiety disorder Int J Clin Med 2 2011 439 443